Illumina Inc.

117.13+3.14+2.75%Vol 2.11M1Y Perf -45.33%
Dec 7th, 2023 16:00 DELAYED
BID117.00 ASK118.00
Open113.24 Previous Close113.99
Pre-Market117.50 After-Market-
 0.37 0.32%  - -
Target Price
258.71 
Analyst Rating
Hold 2.69
Potential %
120.87 
Finscreener Ranking
★+     44.07
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
+     36.58
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     43.55
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
18.81 
Earnings Rating
Strong Sell
Market Cap18.60B 
Earnings Date
9th Nov 2023
Alpha-0.02 Standard Deviation0.11
Beta1.09 

Today's Price Range

113.00117.60

52W Range

89.00238.55

5 Year PE Ratio Range

29.20124.90

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Neutral
Performance
1 Week
6.69%
1 Month
5.81%
3 Months
-26.04%
6 Months
-42.22%
1 Year
-45.33%
3 Years
-65.82%
5 Years
-63.56%
10 Years
18.02%

TickerPriceChg.Chg.%
ILMN117.133.14002.75
AAPL194.271.95001.01
GOOG138.457.02005.34
MSFT370.952.15000.58
XOM98.42-0.6900-0.70
WFC45.400.90002.02
JNJ155.40-1.2200-0.78
FB196.640.99000.51
GE119.48-0.3300-0.28
JPM156.790.48000.31
Financial StrengthValueIndustryS&P 500US Markets
0.60
0.90
0.16
0.37
-135.10
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
66.30
-86.20
-78.20
27.00
-88.38
RevenueValueIndustryS&P 500US Markets
3.50B
22.26
8.95
10.93
Earnings HistoryEstimateReportedSurprise %
Q03 20230.130.33153.85
Q02 20230.020.321.50K
Q01 20230.020.08300.00
Q04 20220.190.14-26.32
Q03 20220.290.3417.24
Q02 20220.630.57-9.52
Q01 20220.871.0722.99
Q04 20210.500.7550.00
Earnings Per EndEstimateRevision %Trend
12/2023 QR-0.01-103.45Negative
12/2023 FY0.68-18.07Negative
3/2024 QR0.12-67.57Negative
12/2024 FY1.06-56.56Negative
Next Report Date-
Estimated EPS Next Report0.13
Estimates Count8
EPS Growth Next 5 Years %22.20
Volume Overview
Volume2.11M
Shares Outstanding158.80K
Shares Float158.44M
Trades Count44.29K
Dollar Volume246.36M
Avg. Volume2.98M
Avg. Weekly Volume2.95M
Avg. Monthly Volume3.64M
Avg. Quarterly Volume2.34M

Illumina Inc. (NASDAQ: ILMN) stock closed at 117.13 per share at the end of the most recent trading day (a 2.75% change compared to the prior day closing price) with a volume of 2.11M shares and market capitalization of 18.60B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 7850 people. Illumina Inc. CEO is Francis A. DeSouza.

The one-year performance of Illumina Inc. stock is -45.33%, while year-to-date (YTD) performance is -42.07%. ILMN stock has a five-year performance of -63.56%. Its 52-week range is between 89 and 238.55, which gives ILMN stock a 52-week price range ratio of 18.81%

Illumina Inc. currently has a PE ratio of -7.60, a price-to-book (PB) ratio of 4.72, a price-to-sale (PS) ratio of 9.31, a price to cashflow ratio of 60.10, a PEG ratio of -0.34, a ROA of -34.58%, a ROC of -36.90% and a ROE of -52.89%. The company’s profit margin is -88.38%, its EBITDA margin is -78.20%, and its revenue ttm is $3.50 Billion , which makes it $22.26 revenue per share.

Of the last four earnings reports from Illumina Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.13 for the next earnings report. Illumina Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Illumina Inc. is Hold (2.69), with a target price of $258.71, which is +120.87% compared to the current price. The earnings rating for Illumina Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Illumina Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Illumina Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.30, ATR14 : 5.28, CCI20 : 135.05, Chaikin Money Flow : 0.22, MACD : -0.55, Money Flow Index : 66.37, ROC : 20.00, RSI : 59.93, STOCH (14,3) : 97.37, STOCH RSI : 1.00, UO : 67.93, Williams %R : -2.63), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Illumina Inc. in the last 12-months were: Aimee L. Hoyt (Option Excercise at a value of $0), Aimee L. Hoyt (Sold 4 788 shares of value $958 789 ), Alexander Aravanis (Option Excercise at a value of $0), Alexander Aravanis (Sold 5 398 shares of value $1 088 982 ), Charles E. Dadswell (Option Excercise at a value of $0), Dadswell Charles (Option Excercise at a value of $0), Francis A. DeSouza (Option Excercise at a value of $0), Hoyt Aimee (Option Excercise at a value of $0), Hoyt Aimee (Sold 5 103 shares of value $994 314 ), Joydeep Goswami (Option Excercise at a value of $0), Kathryne Gambrell Reeves (Option Excercise at a value of $0), Kevin Carl Pegels (Option Excercise at a value of $0), Phillip G. Febbo (Option Excercise at a value of $0), Reeves Kathryne (Option Excercise at a value of $0), Susan H. Tousi (Option Excercise at a value of $0), Susan H. Tousi (Sold 1 000 shares of value $208 075 ), Tousi Susan (Option Excercise at a value of $0), Tousi Susan (Sold 7 000 shares of value $1 434 570 ), TOUSI SUSAN H (Sold 500 shares of value $100 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (31.25 %)
6 (37.50 %)
6 (40.00 %)
Moderate Buy
1 (6.25 %)
1 (6.25 %)
1 (6.67 %)
Hold
7 (43.75 %)
6 (37.50 %)
6 (40.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
3 (18.75 %)
3 (18.75 %)
2 (13.33 %)
Summary RatingHold
2.69
Moderate Buy
2.56
Moderate Buy
2.40

Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.

CEO: Francis A. DeSouza

Telephone: +1 858 202-4500

Address: 200 Illumina Way, San Diego 92122, CA, US

Number of employees: 7 850

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

60%40%

Bearish Bullish

60%40%

 

TipRanks News for ILMN

Mon, 16 Oct 2023 10:02 GMT Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), UnitedHealth (UNH) and BeiGene (BGNE)

- TipRanks. All rights reserved.

Mon, 09 Oct 2023 18:51 GMT EU regulators to order Illumina to divest cancer test firm Grail, FT reports

- TipRanks. All rights reserved.

Fri, 01 Sep 2023 13:55 GMT Early notable gainers among liquid option names on September 1st

- TipRanks. All rights reserved.

News

Stocktwits